≪ View Page

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
treatment_adrenaline [2025/04/16 03:51] – [6.2 Pharmacokinetics] jkohtstreatment_adrenaline [2025/04/29 02:21] (current) – [7. References] jkohts
Line 45: Line 45:
   * **CVS:** hypertension, tachyarrhythmias, myocardial ischemia.   * **CVS:** hypertension, tachyarrhythmias, myocardial ischemia.
   * **CNS:** anxiety, tremor.   * **CNS:** anxiety, tremor.
-  * **MSK:** tissue necrosis if extravasates.+  * **Skin:** tissue necrosis if extravasates.
   * **Metabolic:** hyperglycemia, hyperlactatemia.   * **Metabolic:** hyperglycemia, hyperlactatemia.
  
Line 51: Line 51:
  
 ==== - Pharmacodynamics ==== ==== - Pharmacodynamics ====
-**Mechanism of action:** dose-dependent adrenoceptor activity, with β-agonist effects predominate at low doses, and added α-agonist effects at higher doses.+**Mechanism of action:** Dose-dependent adrenoceptor activity, with β-agonist effects predominate at low doses, and added α-agonist effects at higher doses.
  
 ==== - Pharmacokinetics ==== ==== - Pharmacokinetics ====
Line 75: Line 75:
 ==== - Pharmaceutics ==== ==== - Pharmaceutics ====
 **Formulation:** **Formulation:**
- +  * Ampoules containing 1000 microgram/1 mL or 1000 microgram/10 mL. 
 +  * Autoinjector with varying doses (commonly 0.15 mg, 0.3 mg, 0.5 mg). Various brands exist, e.g. EpiPen, Emerade, Auvi-Q.
 ===== - References ===== ===== - References =====
-Useful general references:+Further Reading:
  
 ~~REFNOTES~~ ~~REFNOTES~~